The shares of CRISPR Therapeutics AG (NASDAQ:CRSP) has been pegged with a rating of In-line by Evercore ISI in its latest research note that was published on February 03, 2020. The Healthcare company has also assigned a $52 price target. Evercore ISI wasn’t the only research firm that published a report of CRISPR Therapeutics AG, with other equities research analysts also giving their opinion on the stock. The stock had earned Outperform rating from Oppenheimer Markets when it published its report on November 12, 2019. That day the Oppenheimer set price target on the stock to $65. The stock was given Buy rating by Jefferies in its report released on August 01, 2019, the day when the price target on the stock was placed at 64. Canaccord Genuity was of a view that CRSP is Buy in its latest report on July 26, 2019. ROTH Capital thinks that CRSP is worth Buy rating. This was contained in the firm’s report on June 10, 2019 in which the stock’s price target was also moved to 50.
Amongst the analysts that rated the stock, 1 have recommended investors to sell it, 3 believe it has the potential for further growth, thus rating it as Hold while 11 advised investors to purchase the stock. The consensus currently stands at a Overweight while its average price target is $79.96. The price of the stock the last time has raised by 52.46% from its 52-Week high price while it is -30.88% than its 52-Week low price. A look at the stock’s other technical shows that its 14-day RSI now stands at 42.06.
The shares of the company dipped by -4.12% during the trading session on Tuesday, reaching a low of $49.62 while ending the day at $51.15. During the trading session, a total of 922506.0 shares were traded which represents a 16.14% incline from the average session volume which is 1.1 million shares. CRSP had ended its last session trading at $53.35. CRISPR Therapeutics AG debt-to-equity ratio currently stands at 0.00, while its quick ratio hovers at 17.30 CRSP 52-week low price stands at $33.55 while its 52-week high price is $74.00.
The company in its last quarterly report recorded $0.51 earnings per share which is above the predicted by most analysts. The CRISPR Therapeutics AG generated 943.77 million in revenue during the last quarter. In the second quarter last year, the firm recorded $2.40 earnings per share. Compared to the same quarter last year, the firm’s revenue was up by 282.35%. CRISPR Therapeutics AG has the potential to record -4.46 EPS for the current fiscal year, according to equities analysts.
Investment analysts at JMP Securities published a research note on November 12, 2019 where it informed investors and clients that Box Inc. (NYSE:BOX) is now rated as Mkt Perform. Berenberg also rated BOX as Initiated on October 10, 2019, with its price target of $18 suggesting that BOX could surge by 13.31% from its current share price. Even though the stock has been trading at $16.89/share, analysts expect it to down by -5.92% to reach $18.33/share. It started the day trading at $16.84 and traded between $15.55 and $15.89 throughout the trading session.
A look at its technical shows that BOX’s 50-day SMA is 16.22 while its 200-day SMA stands at 16.61. The stock has a high of $21.19 for the year while the low is $12.46. The stock, however, witnessed a rise in its short on 02/14/20. Compared to previous close which recorded 8.09 M shorted shares, the short percentage went lower by -12.35%, as 7.09M CRSP shares were shorted. At the moment, only 4.93% of Box Inc. shares were sold short. The company’s average trading volume currently stands at 1.62M shares, which means that the short-interest ratio is just 4.36 days. Over the past seven days, the company moved, with its shift of 5.65%. Looking further, the stock has dropped -12.88% over the past 90 days while it gained 8.61% over the last six months.
The change in the stock’s fortunes has led to several institutional investors altering their holdings of the stock. The The Vanguard Group, Inc. sold more BOX shares, decreasing its portfolio by -2.70% during the last quarter. This move now sees The The Vanguard Group, Inc. selling -456,019 shares in the last quarter, thus it now holds 16,409,346 shares of BOX, with a total valuation of $246,632,470. BlackRock Fund Advisors meanwhile bought more BOX shares in the recently filed quarter, changing its stake to $146,096,815 worth of shares.
Similarly, Starboard Value LP increased its Box Inc. shares by 4.30% during the recently filed quarter. After buying 7,274,896 shares in the last quarter, the firm now controls 300,000 shares of Box Inc. which are valued at $109,341,687. In the same vein, Bares Capital Management, Inc. increased its Box Inc. shares by during the most recent reported quarter. The firm sold 514,671 shares during the quarter which increased its stakes to 5,942,871 shares and is now valued at $89,321,351. Following these latest developments, around 0.20% of Box Inc. stocks are owned by institutional investors and hedge funds.